Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · EyePoint, Inc. (EYPT)

EyePoint to cut about 53% of workforce and end wet AMD trials early after LUCIA miss

Negative Impact 4 of 5 restructuring Written later

EyePoint said its Phase 3 LUCIA trial of DURAVYU in wet AMD did not meet its primary non-inferiority endpoint, and its board approved a plan to reduce operating expenses and focus on diabetic macular edema (DME). The plan cuts the workforce by about 53%, concludes the pivotal wet AMD trials early, and carries about $9 million in employee separation charges, which shareholders would bear as a cost.

Key points

  • The LUCIA wet AMD trial did not meet its primary endpoint of non-inferiority, though it met key secondary endpoints, per the press release.
  • Approximately 53% of positions are affected, with most of the reduction expected in Q4 2026 and completion in the first half of 2027.
  • Estimated aggregate employee separation charges are about $9 million, and annualized savings are estimated at about $30 million.
  • Cash, cash equivalents and short-term investments were about $118 million as of September 30, 2026, a preliminary, unaudited figure; pivotal DME Phase 3 topline data is expected in Q4 2027.

The filing

CompanyEyePoint, Inc. (EYPT)
Form8-K, current report
Filed with the SECOct 19, 2026, 9:22 AM ET
Accession number0001193125-26-424755

Items reported: 2.02 Results of Operations2.05 Exit / Restructuring Costs8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 19, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.